Worth reading
27Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
15
¥100 million (approximately VND 250,000 million)Wording
Conditional
How definitive the wording is.Items stated in the management plan
FormulatedTotal investment planApproximately VND 250,000 million (approximately ¥1.5 billion)
Investment amount by sectorField Construct a new plant for solid-dose pharmaceuticals (tablets and granules) / Amount Approximately VND 250,000 million (approximately ¥1.5 billion)
Key initiatives
01Strengthening Business Portfolio Management
02Create new business opportunities, primarily overseas
03Construct a new plant for solid-dose pharmaceuticals (tablets and granules)
04Expand the product lineup and increase production capacity
Plan assumptionsThe investment is expected to be funded with the subsidiary’s cash on hand. As the plan is still at the planning stage, its details and other aspects may change.
Risks identified by the company
As the plan is still at the planning stage, its details and other aspects may change
| Item | Details |
|---|---|
| Plan name | Ｖｉｓｉｏｎ２０３０ ２ｎｄ ＳＴＡＧＥ |
| Plan period | Construction scheduled to begin in October 2026 to operations scheduled to commence in the second half of 2030 |
| Progress against the plan | Formulated |
| Total investment plan | Approximately VND 250,000 million (approximately ¥1.5 billion) |
| Investment amount by sector | Field Construct a new plant for solid-dose pharmaceuticals (tablets and granules) / Amount Approximately VND 250,000 million (approximately ¥1.5 billion) |
| Plan assumptions | The investment is expected to be funded with the subsidiary’s cash on hand. As the plan is still at the planning stage, its details and other aspects may change. |
| Key initiatives | Strengthening Business Portfolio Management, Create new business opportunities, primarily overseas, Construct a new plant for solid-dose pharmaceuticals (tablets and granules), Expand the product lineup and increase production capacity |
| Risks identified | As the plan is still at the planning stage, its details and other aspects may change |
| Publication date | 30 June 2026 |
Items this document does not state (16)
Sales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceSegment targetNon-financial targetsResults under the previous planReason for revision or withdrawalSize of the Target MarketDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company aims to expand its pharmaceutical business in Vietnam and increase its product lineup and production capacity. It expects this to contribute to the healthcare of people in Vietnam and strengthen its earnings power in the country.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.